Document is current
Any future updates will be listed below
-
Authors
Lv, Meng https://orcid.org/0000-0001-6625-9523
Zheng, Hongli
Pei, Xuying
Lei, Lei
Chen, Wenbo
Bao, Yutong
Ding, Yiyang
Xu, Zhengli
Hu, Lijuan
Wan, Zhe
Zhao, Xueqiang
Zhou, Zhixiao
Lin, Xin https://orcid.org/0000-0003-0956-3654
Huang, Xiaojun https://orcid.org/0000-0002-2145-6643
Wang, Jiasheng
Zhao, Xiangyu
- License Information
-
More Information
Article History
Received: 28 September 2025
Revised: 19 February 2026
Accepted: 27 February 2026
First Online: 1 June 2026
Competing interests
: L.L., X.Q.Z., and X.L. have patents related to LILRB4 STARs. L.L. and H.L.Z. are employees of Bristar Immunotech Limited Co., Ltd. The remaining authors declare that they have no other competing interests.
: The animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of Peking University Health Science Center (CIBR-IACUC-042), and the clinical trial was approved by the Ethics Committee of Peking University People’s Hospital (Ethics Approval Number: 2022PHD007).
